ATRC, US04963C2098

Citizens raises AtriCure target to USD 68 for AtriCure stock

Published on 10/25/2026 at 00:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AtriCure stock heads toward November 3 results after revenue reached USD 153.60 million. Net income was USD 8.96 million in the second quarter.

Targets and earnings calendar

On October 21, Citizens lifted its AtriCure target to USD 68 from USD 52.
Second-quarter revenue reached USD 153.60 million, while net income was USD 8.96 million.
AtriCure is scheduled to release third-quarter results on November 3, 2026.

ATRC, US04963C2098, Illustration mit AI erstellt.

AtriCure stock (ISIN US04963C2098) is heading into its next earnings date after Citizens raised its price target to USD 68 from USD 52 on October 21, 2026. The revision adds a fresh valuation reference before the company reports its third-quarter figures.

Analyst target reaches USD 68

According to Investing.com, Citizens kept a Market Outperform rating while lifting its AtriCure target from USD 52 to USD 68. The firm cited the medical device company's clinical and product pipeline, including opportunities extending into fiscal year 2028.

AtriCure's latest reported quarter provides the operating baseline. In the second quarter of 2026, revenue reached USD 153.60 million and diluted earnings per share were USD 0.18, while net income was USD 8.96 million, according to MarketBeat.

Three target changes since October 2

MarketBeat reported a sequence of dated analyst actions: Freedom Capital cut its rating to Hold and raised its target to USD 57 on October 2, 2026; BTIG raised its target from USD 55 to USD 63 on October 12, 2026; and Citizens raised its target from USD 52 to USD 68 on October 21, 2026.

What does the target reset mean?

The target moved USD 16 above Citizens' previous USD 52 view, a 30.77 percent increase. That change is larger than the company's second-quarter revenue beat against the USD 151.80 million consensus cited by MarketBeat, which was USD 1.80 million, or 1.19 percent, below reported revenue. The valuation debate therefore depends on whether pipeline programs and pain-management products can translate into sustained revenue growth.

November 3 sets the next date

Business Wire reported that AtriCure will release third-quarter 2026 results on November 3, 2026, followed by a conference call at 4:30 p.m. ET.

Valuation remains near the yearly high

AtriCure closed at USD 58.97 on Nasdaq on October 23, 2026 at 4:00 p.m. ET. Its market capitalization was USD 3.0 billion, and the 52-week range was USD 25.36 to USD 61.70 as of that trading date; the close stood 4.42 percent below the high.